Education
About Us
Working with TipRanks
Follow Us
Seres Therapeutics (DE:1S90)
FRANKFURT:1S90
1S90 Analyst Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
1S90 Stock 12 Month Forecast
Average Price Target
€12.02
▼(-14.18% Downside)
| Highest Price Target€12.02 | Average Price Target€12.02 | Lowest Price Target€12.02 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TD Cowen
―
Buy
―
Reiterated
08/06/25
Canaccord Genuity
€11.99
Buy
-14.37%
Downside
Reiterated
08/06/25
Chardan Capital
€5.14
Hold
-63.30%
Downside
Downgraded
05/08/25
TR | OpenAI - 4o
―
Hold
―
Reiterated
04/26/25
Piper Sandler
€17.13
Hold
22.34%
Upside
Reiterated
03/14/25
J.P. Morgan
―
Sell
―
Downgraded
10/23/24
Goldman Sachs
€18.84
Sell
34.57%
Upside
Reiterated
08/14/24
Seres Therapeutics Inc. (MCRB): 2Q24: Vowst asset sale moving forward. SER-155 data in September. 14 August 2024 | 9:44PM EDT Seres Therapeutics (MCRB) reported 2Q24 results including Vowst sales of $14mn, which was slightly below our $16.0mn estimate. Net loss in the quarter of ($32.9mn) and EPS loss of ($0.22), compared to our loss estimate of ($0.27). Lower operating expenses derived from shifts in R&D expenditure and headcount reductions (~41%) that had been announced in 4Q23, which are estimated to generate savings on an annualized basis of $75-$85mn. A further update was provided last week regarding the June announcement of an agreement to sell the remainder of rights to Vowst to their commercial partner, Nestle.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TD Cowen
―
Buy
―
Reiterated
08/06/25
Canaccord Genuity
€11.99
Buy
-14.37%
Downside
Reiterated
08/06/25
Chardan Capital
€5.14
Hold
-63.30%
Downside
Downgraded
05/08/25
TR | OpenAI - 4o
―
Hold
―
Reiterated
04/26/25
Piper Sandler
€17.13
Hold
22.34%
Upside
Reiterated
03/14/25
J.P. Morgan
―
Sell
―
Downgraded
10/23/24
Goldman Sachs
€18.84
Sell
34.57%
Upside
Reiterated
08/14/24
Seres Therapeutics Inc. (MCRB): 2Q24: Vowst asset sale moving forward. SER-155 data in September. 14 August 2024 | 9:44PM EDT Seres Therapeutics (MCRB) reported 2Q24 results including Vowst sales of $14mn, which was slightly below our $16.0mn estimate. Net loss in the quarter of ($32.9mn) and EPS loss of ($0.22), compared to our loss estimate of ($0.27). Lower operating expenses derived from shifts in R&D expenditure and headcount reductions (~41%) that had been announced in 4Q23, which are estimated to generate savings on an annualized basis of $75-$85mn. A further update was provided last week regarding the June announcement of an agreement to sell the remainder of rights to Vowst to their commercial partner, Nestle.
Best Analysts Covering Seres Therapeutics
1 Month
xxx
Success Rate
12/21 ratings generated profit
Average Return
+4.38%
reiterated a xxx
rating a year ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 57.14% of your transactions generating a profit, with an average return of +4.38% per trade.
3 Months
xxx
Success Rate
12/21 ratings generated profit
Average Return
+15.13%
reiterated a xxx
rating a year ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +15.13% per trade.
1 Year
Success Rate
11/32 ratings generated profit
Average Return
+51.04%
reiterated a buy rating 10 days ago
Copying John Newman's trades and holding each position for 1 Year would result in - of your transactions generating a profit, with an average return of +51.04% per trade.
2 Years
xxx
Success Rate
16/21 ratings generated profit
Average Return
+218.08%
reiterated a xxx
rating a year ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 76.19% of your transactions generating a profit, with an average return of +218.08% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
1S90 Analyst Recommendation Trends
Rating
Jan 25
Mar 25
Apr 25
May 25
Aug 25
Strong Buy
2
3
2
3
1
Buy
2
2
2
2
3
Hold
15
13
7
5
3
Sell
2
0
1
1
1
Strong Sell
0
0
0
0
0
total
21
18
12
11
8
Each month's total comprises the sum of three months' worth of ratings.
1S90 Financial Forecast
1S90 Stock Forecast FAQ
What is DE:1S90’s average 12-month price target, according to analysts?
Based on analyst ratings, Seres Therapeutics’s 12-month average price target is 12.02.
What is DE:1S90’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for DE:1S90, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Seres Therapeutics a Buy, Sell or Hold?
Seres Therapeutics has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
What is Seres Therapeutics’s share price target?
The average share price target for Seres Therapeutics is 12.02. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €12.02 ,and the lowest forecast is €12.02. The average share price target represents -14.18% Decrease from the current price of €14.
The highest analyst share price target is €12.02 ,and the lowest forecast is €12.02. The average share price target represents -14.18% Decrease from the current price of €14.
What do analysts say about Seres Therapeutics?
Seres Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of Seres Therapeutics?
To buy shares of DE:1S90, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.